Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
YMAB | US
0.08
0.57%
Healthcare
Biotechnology
30/06/2024
04/10/2024
14.16
13.78
14.22
13.44
Y-mAbs Therapeutics Inc. a commercial-stage biopharmaceutical company focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics Inc. was incorporated in 2015 and is headquartered in New York New York.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
46.1%1 month
58.6%3 months
69.2%6 months
65.1%-
119.05
6.05
0.01
0.01
-0.43
5.78
-
-27.00M
631.11M
631.11M
-
-42.94
-
9.90
-24.61
13.27
10.85
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.70
Range1M
1.80
Range3M
7.29
Rel. volume
0.39
Price X volume
1.39M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 13.88 | 690.21M | 8.44% | n/a | 0.00% |
CureVac N.V | CVAC | Biotechnology | 3.02 | 679.69M | 0.67% | n/a | 10.37% |
Avid Bioservices Inc | CDMO | Biotechnology | 10.63 | 678.14M | -1.02% | n/a | 353.77% |
ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 9.61 | 677.91M | -1.84% | n/a | 0.92% |
Mereo BioPharma Group plc | MREO | Biotechnology | 4.4 | 676.95M | 2.56% | n/a | 7.83% |
ATXS | ATXS | Biotechnology | 11.87 | 669.77M | 2.06% | n/a | 1.67% |
ANNX | ANNX | Biotechnology | 6.29 | 664.56M | -2.02% | n/a | 8.36% |
OLMA | OLMA | Biotechnology | 11.6 | 664.29M | -3.73% | n/a | 0.86% |
Humacyte Inc | HUMA | Biotechnology | 5.44 | 650.86M | -4.39% | n/a | -63.37% |
Arcturus Therapeutics Ltd | ARCT | Biotechnology | 23.88 | 645.77M | -6.28% | n/a | 11.94% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.43 | 0.76 | Cheaper |
Ent. to Revenue | 5.78 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 6.05 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 69.15 | 74.67 | Par |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 631.11M | 3.73B | Emerging |